Shionogi & Co., Ltd.
Clinical trials sponsored by Shionogi & Co., Ltd., explained in plain language.
A Japanese pharmaceutical company focused on infectious diseases and pain management.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New RSV drug trial aims to protect vulnerable adults Results expected Dec 2026 (estimated)
- New drug combo targets breathing pauses in sleep apnea Results expected Dec 2026 (estimated)
- Can a new pill shorten COVID-19 symptoms? Results expected Jul 2027 (estimated)
- New pill could boost breathing in pompe disease – early trial underway Results expected Aug 2027 (estimated)
-
Can an oral pill ease breathing and muscle weakness in pompe disease?
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral medication called S-606001 in adults with late-onset Pompe disease, a condition that causes progressive muscle weakness and breathing problems. The main goal is to see if the drug is safe and tolerable. Researchers will also …
Phase 1 • Sponsor: Shionogi • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can an oral pill boost muscle strength in pompe disease?
Disease control Not yet recruitingThis study tests the long-term safety and effectiveness of an experimental oral drug called S-606001 in adults with late-onset Pompe disease, a genetic condition that causes progressive muscle weakness. Participants who completed a prior S-606001 study can join, and they will rec…
Phase 2 • Sponsor: Shionogi • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC